GLTO
Damora Therapeutics, Inc.
Key Financials
Net Income
$-209839000
↓ 878.8%
Operating Income
$-210872000
↓ 847.3%
EPS (Diluted)
$3.98
↑ 121.5%
Shareholders' Equity
$240.4M
↑ 1418.4%
Total Assets
$260.5M
↑ 1420.7%
Total Liabilities
$20.1M
↑ 1448.6%
Cash & Equivalents
$257.6M
↑ 1717.5%
Operating Cash Flow
$-6726000.00
↑ 63.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 8/13/2026 | View on SEC |
| 3 | 8/13/2026 | View on SEC |
| EFFECT | 8/12/2026 | View on SEC |
| S-8 POS | 8/10/2026 | View on SEC |
| S-8 POS | 8/10/2026 | View on SEC |
| POSASR | 8/10/2026 | View on SEC |
| S-8 POS | 8/10/2026 | View on SEC |
| S-8 POS | 8/10/2026 | View on SEC |
| S-8 POS | 8/10/2026 | View on SEC |
| S-8 POS | 8/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GLTO |
| Company Name | Damora Therapeutics, Inc. |
| CIK | 1800315 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (781) 281-9020 |